Oric Pharmaceuticals Inc. (ORIC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORIC Stock Price Chart Interactive Chart >
ORIC Price/Volume Stats
|Current price||$3.20||52-week high||$21.18|
|Prev. close||$3.24||52-week low||$2.62|
|Day high||$3.31||Avg. volume||383,469|
|50-day MA||$3.87||Dividend yield||N/A|
|200-day MA||$6.23||Market Cap||126.65M|
Oric Pharmaceuticals Inc. (ORIC) Company Bio
Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Most Popular Stories View All
ORIC Latest News Stream
|Loading, please wait...|
ORIC Latest Social Stream
View Full ORIC Social Stream
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
ORIC Price Returns